Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -6.54% is 757% below its 5-year average of -0.76%, near the low end of its 5-year range (-19.18%–36.33%).
As of the fiscal period ended Tuesday, September 30, 2025. 49.14% above its 12-month average of -12.86%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-09-30.
RETURN ON EQUITY (ROE)
-6.54%
RETURN ON EQUITY (ROE) AVG TTM
-12.86%
RETURN ON EQUITY (ROE) AVG 3Y
-15.03%
RETURN ON EQUITY (ROE) AVG 5Y
-0.76%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+49.14%
CURRENT VS 3Y AVG
+56.49%
CURRENT VS 5Y AVG
-756.77%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+84.43%
vs the sector median at left
Universe Pharmaceuticals Inc.
Market Cap
$2.66M
Return on Equity (ROE)
-6.54%
TTM Avg
-12.86%
3Y Avg
-15.03%
5Y Avg
-0.76%
Market Cap
$2.69M
Return on Equity (ROE)
-657.69%
TTM Avg
-358.53%
3Y Avg
-220.37%
5Y Avg
-149.08%
Market Cap
$2.56M
Return on Equity (ROE)
N/A
TTM Avg
-419.35%
3Y Avg
-396.40%
5Y Avg
-293.00%
Market Cap
$2.54M
Return on Equity (ROE)
-402.92%
TTM Avg
-276.14%
3Y Avg
-197.40%
5Y Avg
-116.89%
Market Cap
$2.86M
Return on Equity (ROE)
-141.90%
TTM Avg
-194.17%
3Y Avg
-143.89%
5Y Avg
-113.05%
Market Cap
$2.44M
Return on Equity (ROE)
-554.01%
TTM Avg
-109.66%
3Y Avg
1542.76%
5Y Avg
920.25%
Market Cap
$2.94M
Return on Equity (ROE)
-106.79%
TTM Avg
-210.00%
3Y Avg
-362.69%
5Y Avg
1766.26%
Market Cap
$2.38M
Return on Equity (ROE)
-261.73%
TTM Avg
-293.81%
3Y Avg
-189.35%
5Y Avg
-145.76%
Market Cap
$2.38M
Return on Equity (ROE)
-53.49%
TTM Avg
-904.74%
3Y Avg
-509.27%
5Y Avg
-319.78%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Universe Pharmaceuticals Inc. (UPC) | $2.66M | -6.54% | -12.86% | -15.03% | -0.76% |
| iSpecimen Inc. (ISPC)vs › | $2.69M | -657.69% | -358.53% | -220.37% | -149.08% |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | N/A | -419.35% | -396.40% | -293.00% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | -402.92% | -276.14% | -197.40% | -116.89% |
| IceCure Medical Ltd (ICCM)vs › | $2.86M | -141.90% | -194.17% | -143.89% | -113.05% |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | -554.01% | -109.66% | 1542.76% | 920.25% |
| Revelation Biosciences, Inc. (REVB)vs › | $2.94M | -106.79% | -210.00% | -362.69% | 1766.26% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | -261.73% | -293.81% | -189.35% | -145.76% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | -53.49% | -904.74% | -509.27% | -319.78% |
| Onconetix, Inc. (ONCO)vs › | $2.37M | -75.70% | -349.85% | -22.96% | -60.31% |
ROE
-6.5%
ROA
-5.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-30 | -6.54% |
| 2024-09-30 | -19.18% |
| 2023-09-30 | -15.59% |
| 2022-09-30 | -18.81% |
| 2021-09-30 | 19.21% |
| 2020-09-30 | 36.33% |
| 2019-09-30 | 60.98% |
| 2018-09-30 | 78.53% |
